Palisade Bio (PALI) Change in Receivables (2011 - 2023)
Palisade Bio (PALI) posted quarterly Change in Receivables of $250000.0 for Q1 2023, up 523.73% quarter-over-quarter from -$59000.0 in Q3 2021.
Palisade Bio (PALI) Change in Receivables (2011 - 2023) Analysis & Trends
Palisade Bio (PALI) has reported Change in Receivables for 12 consecutive years, with $250000.0 the latest figure, recorded in Q1 2023.
- In Q1 2023, Change in Receivables changed N/A year-over-year to $250000.0; the TTM figure through Mar 2024 stood at $250000.0 (changed 0.0% YoY), while the FY2021 annual figure was -$84000.0, down 242.37% from the prior year.
- Change in Receivables rose to $250000.0 in Q1 2023 per PALI's latest filing, from -$59000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $250000.0 in Q1 2023 and bottomed at -$108751.0 in Q3 2019.
- Historically, Change in Receivables has averaged -$4363.0 across 4 years, with a median of -$40090.0 in 2019.
- Annual changes were most pronounced in 2020 — Change in Receivables soared 181.1% — and 2021, when it sank 2778.05%.
- Palisade Bio's Change in Receivables stood at -$40090.0 in 2019, then soared by 114.97% to $6000.0 in 2020, then slumped by 1083.33% to -$59000.0 in 2021, then jumped by 523.73% to $250000.0 in 2023.
- Business Quant data shows PALI's Change in Receivables at $250000.0 in Q1 2023, -$59000.0 in Q3 2021, and $34000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 250,000.00 |
| Mar 31, 2023 | 250,000.00 |
| Sep 30, 2021 | -59,000.00 |
| Sep 30, 2021 | -59,000.00 |
| Jun 30, 2021 | 34,000.00 |
| Jun 30, 2021 | 34,000.00 |
| Mar 31, 2021 | -59,000.00 |
| Mar 31, 2021 | -59,000.00 |
| Dec 31, 2020 | 6,000.00 |
| Dec 31, 2020 | 6,000.00 |
| Jun 30, 2020 | 55,050.00 |
| Jun 30, 2020 | 55,050.00 |
| Mar 31, 2020 | -2,050.00 |
| Mar 31, 2020 | -2,050.00 |
| Dec 31, 2019 | -40,090.00 |
| Dec 31, 2019 | -40,090.00 |
| Sep 30, 2019 | -108,751.00 |
| Sep 30, 2019 | -108,751.00 |
| Jun 30, 2019 | -67,877.00 |
| Jun 30, 2019 | -67,877.00 |